Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Infectious Disease
•
Tuberculosis
•
Inflammatory eye disorders
•
Scleritis
•
Ophthalmology
•
General Infectious Disease
How do you approach treatment of tuberculous scleritis in pregnancy?
Related Questions
What are your top takeaways from ID Week 2024?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
What is your approach to duration of systemic antibiotics for treatment of isolated bacterial endophthalmitis in the absence of bacteremia or other deep-seated metastatic foci of infection?
What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?
How often do you see bony erosions in patients with Lyme arthritis?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
How would you approach management of nodular scleritis in the setting of suspected GCA?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?
